Search by drug, manufacturer, or indication

Displaying 1041 - 1050 of 1165

Janumet (sitagliptin phosphate)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated February 8, 2016

Zykadia (ceritinib)

Status:

Negotiations were not pursued

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Non-Small Cell Lung Cancer (metastatic)

Last updated February 5, 2016

Cimzia (certolizumab pegol)

Status:

Concluded with an LOI

Manufacturer:

UCB Canada Inc.

Indication:

Ankylosing spondylitis

Last updated January 6, 2016

Opsumit (macitentan)

Status:

Concluded without agreement

Manufacturer:

Actelion Pharmaceuticals Ltd.

Indication:

Pulmonary Arterial Hypertension

Last updated December 18, 2015

Actemra SC (tocilizumab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Rheumatoid Arthritis

Last updated December 16, 2015

Incruse Ellipta (umeclidinium)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Last updated December 15, 2015

Duaklir Genuair (aclidinium bromide/formoterol fumarate dihydrate)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Last updated December 15, 2015

Inflectra (infliximab)

Status:

Concluded with an LOI

Manufacturer:

Hospira Healthcare Corporation

Indication:

Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis

Last updated November 19, 2015

Bosulif (bosutinib)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Chronic Myeloid Leukemia

Last updated November 9, 2015

Avastin (bevacizumab)

Status:

Concluded with an LOI

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Cervical Cancer

Last updated November 4, 2015